Previous 10 | Next 10 |
2024-05-22 17:43:22 ET Several vaccine makers closed Wednesday up with double-digit percentage gains amid a report of the first avian flu case in a human in Australia and a second case in the U.S.... Read the full article on Seeking Alpha For further details see: Moderna...
2024-05-22 17:15:03 ET BMO Capital analyst issues OUTPERFORM recommendation for PFE on May 22, 2024 03:48PM ET. The previous analyst recommendation was Outperform. PFE was trading at $29.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-05-22 17:10:18 ET This article was first published on The Motley Fool’s U.S. website. Stocks have been a wealth-creating machine for investors over the long run. Though other asset classes have delivered a positive nominal return to patient investors, including gold, oil...
2024-05-22 17:00:09 ET Evan Seigerman from BMO Capital issued a price target of $36.00 for PFE on 2024-05-22 15:48:00. The adjusted price target was set to $36.00. At the time of the announcement, PFE was trading at $29.6. The overall price target consensus is at $57.55 ...
2024-05-22 16:29:53 ET Summary Today, we take a more in-depth look at drug giant Pfizer Inc., which has experienced falling revenues as Covid-19 has become endemic. The acquisition of Seagen did add blockbuster oncology therapies to Pfizer's portfolio, boosting sagging oncology sa...
2024-05-22 14:00:26 ET More on BioNTech, Moderna, etc. Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs Aggressive Strides Forward For Moderna's Cancer Vaccine Pfizer Stock: Rebound Has Started (Technical Analysis) Pfizer launchi...
2024-05-22 12:59:29 ET More on Pfizer Pfizer tax practices targeted by Senate Finance Committee Chair Wyden Pfizer agrees to pay up to $250M to settle Zantac cancer lawsuits - report Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs ...
2024-05-21 17:22:48 ET More on Pfizer Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs Pfizer Stock: Rebound Has Started (Technical Analysis) Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield Pfizer agrees t...
2024-05-21 10:00:00 ET Summary Pfizer shares have lagged behind the pharma rally due to inflated expectations, one-time losses, write-offs, and the Seagen acquisition. The company is expecting an LOE wave with 6 names facing patent expirations, leading to a $17 billion sales decli...
2024-05-21 07:30:00 ET Summary Retirement investing can be challenging due to diverse needs and unique financial situations. Inflation reduces purchasing power and higher withdrawal rates impact net worth, making high-quality income stocks important. I highlight two ETFs and t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...